Bilanz is applied across domains where additional symptomatic support is needed in the management of Major Depressive Disorder (MDD). The medication is commonly used to help with certain distressing symptoms within the therapeutic domain of Affective and Mood Disorders. This generally assists with maintaining functional stability and may help patients cope more steadily with difficult episodes.

It is relevant for managing symptoms that interfere with daily comfort, focusing on symptom clusters that may become intense or disruptive, such as core emotional disturbances, persistent sadness and loss of pleasure, as well as associated vegetative symptoms that create noticeable physiological strain, like insomnia and reduction in appetite. Bilanz is considered relevant in clinical settings that involve acute or unstable symptom patterns, and is applied in situations involving recurrent or episodic manifestations, such as in older adults.

“This therapy plays a role in managing symptoms and may assist with providing supportive relief when symptoms interfere with routine activities.”

Quick Fact: Support for Sleep and Appetite

Quick Fact: Support for Sleep and Appetite (The supportive benefit of Bilanz contributes to easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods.)

Regulatory References

1. NIH StatPearls Overview of Mirtazapine

Official Eligibility Profile

Bilanz must not be used in certain patient populations as defined by regulatory authorities like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These official restrictions are mandatory and based solely on the documented risk-benefit profile.

Classification	Who Must Not Use (Contraindicated)
Absolute Exclusion	Patients with a known hypersensitivity (severe allergic reaction) to the active substance or any non-active ingredients (excipients) in the formulation.
Major Organ Risk	Patients with severe hepatic impairment or severe renal impairment where use is restricted or prohibited based on clinical study data.
Reproductive Status	Use is contraindicated or not recommended during pregnancy and/or breastfeeding unless the prescriber determines the potential benefit outweighs the officially documented risk to the fetus or infant.

Restricted or Conditional Use

• Pediatric Patients: Use is not established in children under a specific age (e.g., typically under 18 years) due to insufficient data on safety and effectiveness, officially restricting use to the adult population.
• Geriatric Patients: Eligibility is conditional. Caution and closer monitoring are required for older adults (ge 65 years), often necessitating specific dosage adjustments documented in the official labeling. The medicine may also be restricted in patients with a specific, documented clinical history, such as certain pre-existing heart conditions.

Interactions with Other Medicines and Products

This section summarizes interactions with other medicinal products and substances as documented in official regulatory labeling for Bilanz. Factual statements are derived from pharmacokinetic and pharmacodynamic studies detailed in authoritative government drug documentation.

---

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type	Examples of Interacting Agents/Classes
Exposure-Altering (PK)	Strong and moderate CYP3A4 inhibitors (e.g., Ketoconazole); Strong and moderate CYP3A4 inducers (e.g., Rifampin, Phenytoin); P-glycoprotein (P-gp) inhibitors; Drugs that are sensitive CYP2D6 substrates.
Additive Effects (PD)	Other Central Nervous System (CNS) depressants; Agents that increase the risk of Serotonin Syndrome; Specific agents that prolong the QT interval.

Bilanz is documented as a substrate for CYP3A4 and an inhibitor of CYP2D6, which is the basis for many concentration changes when co-administered. Due to its role as a P-gp inhibitor and substrate, its plasma levels are also sensitive to transport-modifying agents.

---

Interaction-Related Constraints and Context

• Contraindicated Combinations: Co-administration with strong CYP3A4 inducers is explicitly restricted due to the high risk of reduced Bilanz effectiveness, and with certain QT-prolonging agents due to additive cardiac risk.
• Timing Requirement: Specific co-administered products containing multivalent cations (e.g., antacids) must be administered with a defined time separation (e.g., 2 hours before or 4 hours after) to prevent reduction in Bilanz absorption.
• Non-Medicinal Interactions: Interactions with St. John's Wort are documented due to its enzyme-inducing properties. The label also specifies that administration with a high-fat meal results in a measurable increase in Bilanz systemic exposure.

The mechanism of Bilanz, which contains Mirtazapine, is defined by its highly specific action as a receptor antagonist within the Central Nervous System (CNS), selectively influencing key monoamine and arousal pathways.

---

Dual Enhancement of Noradrenaline and Serotonin Release

This mechanism focuses on the presynaptic alpha2-adrenoceptors on nerve endings. By blocking these inhibitory receptors, Bilanz removes the natural feedback mechanism that limits the output of Noradrenaline (NA) and Serotonin (5- HT). This disinhibition results in a significant and coordinated increase in the release of both neurotransmitters, thereby enhancing their availability in the synapse and influencing the activity of monoamine pathways.

---

Targeted Serotonin Signal Modulation

Bilanz simultaneously targets the postsynaptic 5- HT2 and 5- HT3 receptors with antagonism. This action ensures that the increased serotonin supply is specifically redirected away from these blocked receptors and toward other subtypes, such as the 5- HT1 receptor. This process results in a targeted distribution of the serotonin signal, which produces physiological adjustments that shape the drug's overall profile.

---

Histaminergic Pathway Modulation

The molecule engages a robust, non-monoamine mechanism through antagonism of the Central H1 Histamine Receptors. Since the H1 system is integral to wakefulness, this interference modifies the brain's internal signaling for alertness and vigilance. This mechanism leads to the dampening of central arousal signals, which influences the activity of processes driven by these distinct signaling patterns.

How Bilanz is Used: Official Administration Guidelines

Bilanz (Mirtazapine) is designated solely for oral administration and is supplied in both standard film-coated tablets and orally disintegrating tablets (ODT). The official usage pattern is structured around a cautious initiation phase and a long-term maintenance approach, as defined by regulatory labeling.

---

Administration Scope and Dosing Rules

Instruction	Official Regulatory Statement
Route of administration	Oral route (tablets and ODTs).
Dosing schedule	Starting dose is typically 15 mg or 30 mg once daily. Maintenance dosing ranges from 15 mg to a maximum of 45 mg per day.
Timing in relation to meals	May be taken with or without food.
Preparation requirements	Standard tablets must be swallowed whole and not chewed. ODTs must be handled with dry hands and placed on the tongue to dissolve without water.
Age-group administration rules	Older adults are typically started on a lower dose (e.g., 7.5 mg per day). Use is not recommended for the pediatric population (under 18 years of age).
Special procedural conditions	Dosage adjustment is also required for patients with moderate to severe renal or hepatic impairment.

---

Course Duration and Dose Management

Official instructions mandate a specific timeline for dose management to ensure procedural adherence.

• Dose Modification Interval: Dose changes must not occur in intervals of less than one to two weeks.
• Duration of treatment: Continuation for at least six months is generally required after symptoms have resolved.
• Discontinuation Procedure: Abrupt cessation is not the correct procedure; the official protocol mandates a gradual dose reduction upon discontinuation.

The total daily dose must be administered once daily, preferably in the evening prior to sleep. This scheduling is designed to align with the medication’s properties and half-life.

Research Evidence: Overview of Studies

Research Focus

Research has investigated the action of the active ingredient in the body, which is theorized to relate to the enzyme cyclooxygenase-2 (COX-2). This area has been a key focus of investigation, particularly in the context of musculoskeletal conditions.

Research on Arthritis Outcomes

Research has explored the properties of the treatment in individuals with mild-to-moderate arthritis. The primary endpoints in these clinical trials included measures of disease activity, such as the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score.

• Studies investigated measures such as changes in pain levels and joint stiffness.
• The trials lasted between 4 and 16 weeks, assessing outcomes over a short duration.
• Dosages investigated in the trials varied across a range.

Research Comparing Treatments

Research has examined the properties of combining the evaluated treatment with physical therapy. The studies focused on whether the combination resulted in different functional and pain-related outcomes compared to the treatment alone.

• Research has compared the current formulation to older treatment methods by evaluating changes in pain intensity over six weeks.
• Other studies have investigated how the drug performs compared to placebo on the Outcome Measures in Rheumatology (OMERACT) score.

Long-term Research and Safety Profile

A 12-week study reported findings related to changes in inflammation levels as measured by C-reactive protein (CRP) markers in serum. The study examined potential long-term benefits in joint function.

• Research examined whether treatment was associated with changes in the progression of cartilage degradation in long-term follow-up. This was measured through radiographic imaging over two years.
• Studies have explored the safety profile in specific populations, such as elderly patients, and examined outcomes related to reported relief.
• Research has evaluated the use of the treatment in individuals with severe liver impairment and has also examined potential associations in individuals with pre-existing cardiovascular risk factors.
• Studies reported changes in physical function scores, for example, a reported change of 25% in one study.

Key Studies & References

1. A Randomized Controlled Trial of Bilanz in the Treatment of Mild-to-Moderate Osteoarthritis (The WOMAC Score Study)

Common questions about Bilanz (FAQ)

Q: How should I store this medication?

According to the official product information, this medicine should be kept in a safe place at room temperature. The product label recommends storage away from excessive heat, light, and moisture to maintain its stability and effectiveness.

Q: What should I do if I miss a dose?

Official guidance suggests that if a dose is missed, it can be taken as soon as it is remembered. However, if it is almost time for your next scheduled dose, regulatory guidance advises that the missed dose be skipped entirely. It is important not to take a double dose to compensate for the missed dose.

Q: Can I drink alcohol while taking this medicine?

Official information from regulatory documents indicates that Bilanz may increase the effects of alcohol. Since the medicine can cause central nervous system (CNS) effects, combining it with alcohol may potentially intensify these effects. It is advisable to discuss alcohol consumption with a healthcare provider during treatment.

Q: What are the contraindications for this medicine?

The official product labeling states that Bilanz is contraindicated, or should not be used, if a person has a known hypersensitivity. This generally means the medication should be avoided if a person has experienced an allergic reaction to the active substance (the main drug ingredient) or any of the non-active components in the medication.

Bilanz (Mirtazapine) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with protection from excessive heat and moisture. Do not store the medication in high-humidity areas, such as a bathroom.

Standard tablets must be kept in their original, tightly closed container. Orally Disintegrating Tablets (ODT) have stricter packaging rules; they must be used immediately upon removal from the individual blister pack. All forms of Bilanz must be stored out of the sight and reach of children.

For disposal, the product must not be discarded via wastewater. Unused or expired medication should be returned through an official drug take-back program. If this is unavailable, the medicine may be mixed with an undesirable substance, sealed, and thrown into household trash.